Yes Vinn thanks, I’m aware of all this. I’m also aware of the equally strong (stronger?) rationale for the IL-6 inhibitor tocilizumab for Covid 19 CRS, which by the way is FDA approved for CRS caused by CAR- T therapies, but know this still needs to be tested in Covid. Nobody is saying that MSC doesn’t work- it’s more that the data from this announcement doesn’t prove it.
cheers
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-448
-
- There are more pages in this discussion • 400 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.0¢ |
Change
-0.020(2.08%) |
Mkt cap ! $1.073B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | 97.0¢ | 93.5¢ | $1.424M | 1.507M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 29390 | 93.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 14089 | 2 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |